Abstract
The effect of an oral dose of 20 mg of rifampin per kg per day on the immune response to killed Mycobacterium bovis var. BCG, 1-chloro-2,4-dinitrobenzene (DNCB), and sheep red blood cells (SRBC) was studied in adult female guinea pigs. Fully established cutaneous reactions to BCG or DNCB were markedly reduced during rifampin treatment but reverted to pretreatment levels after the drug was discontinued. When treatment was begun 7 days after immunization, positive reactions did not occur during drug administration but developed after cessation. When treatment was initiated 7 days before immunization, the response to these agents was completely suppressed during but also after rifampin was discontinued, suggesting that recognition and processing of the immunogens had been impaired. Rifampin had no effect on the secondary response to SRBC. When treatment was initiated either 7 days before or 2, 3, or 4 days after SRBC immunization, the primary response was abolished, but the reaction to a booster after drug withdrawal varied: some animals developed a normal secondary hemagglutinin response, but the majority reacted as if they had not been previously immunized. These studies indicate that rifampin is an active immunosuppressive agent in the guinea pig.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dajani B. M., Canady M. S., Thompson J. S., Kasik J. E. Rifampicin: an immunosuppressant? Lancet. 1972 Nov 18;2(7786):1094–1094. doi: 10.1016/s0140-6736(72)92390-2. [DOI] [PubMed] [Google Scholar]
- Devine L. F., Johnson D. P., Rhode S. L., 3rd, Hagerman C. R., Pierce W. E., Peckinpaugh R. O. Rifampin: effect of two-day treatment on the meningococcal carrier state and the relationship to the levels of drug in sera and saliva. Am J Med Sci. 1971 Feb;261(2):79–83. doi: 10.1097/00000441-197102000-00004. [DOI] [PubMed] [Google Scholar]
- Newman R., Doster B., Murray F. J., Ferebee S. Rifampin in initial treatment of pulmonary tuberculosis. A U.S. Public Health Service tuberculosis therapy trial. Am Rev Respir Dis. 1971 Apr;103(4):461–476. doi: 10.1164/arrd.1971.103.4.461. [DOI] [PubMed] [Google Scholar]
- Nilsson B. S. Rifampicin: an immunosuppressant? Lancet. 1971 Aug 14;2(7720):374–374. doi: 10.1016/s0140-6736(71)90087-0. [DOI] [PubMed] [Google Scholar]
- Păunescu E. In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin. Nature. 1970 Dec 19;228(5277):1188–1190. doi: 10.1038/2281188a0. [DOI] [PubMed] [Google Scholar]
- Raleigh J. W. Rifampin in treatment of advanced pulmonary tuberculosis. Report of a VA cooperative pilot study. Am Rev Respir Dis. 1972 Mar;105(3):397–409. doi: 10.1164/arrd.1972.105.3.397. [DOI] [PubMed] [Google Scholar]
- Serrou B., Solassol C., Karcenty L., Joyeux H., Pujol H. Action immunodépressive de la rifampicine. Nouv Presse Med. 1972 May 6;1(19):1295–1295. [PubMed] [Google Scholar]
- Severson C. D., Thompson J. S. Quantitative semi-micro hemagglutination. A sensitive assay dependent upon cellular dissociation and migration in capillary tubes. J Immunol. 1966 May;96(5):785–789. [PubMed] [Google Scholar]
- UHR J. W., FINKELSTEIN M. S. Antibody formation. IV. Formation of rapidly and slowly sedimenting antibodies and immunological memory to bacteriophage phi-X 174. J Exp Med. 1963 Mar 1;117:457–477. doi: 10.1084/jem.117.3.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Valente G., Luvarà A. Sperimentazione clinica della rifampicina in campo pediatrico. Attività terapeutica e tollerabilità. Clin Pediatr (Bologna) 1969 Jan;51(1):48–55. [PubMed] [Google Scholar]